Analyzing Eloxx Pharmaceuticals (ELOX) and Its Competitors

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Eloxx Pharmaceuticals to similar businesses based on the strength of its risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-10.39
Eloxx Pharmaceuticals Competitors	$3.55 billion	$3.14 billion	547.53

Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for Eloxx Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Eloxx Pharmaceuticals Competitors	7616	13668	25502	1003	2.42

Eloxx Pharmaceuticals presently has a consensus target price of $38.33, indicating a potential upside of 139.58%. As a group, “Pharmaceuticals” companies have a potential upside of 28.13%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.23%	-223.52%	-16.98%

Risk & Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, suggesting that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.17, suggesting that their average share price is 417% less volatile than the S&P 500.

Insider & Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.